title: Long-term survival in multiple myeloma: a single-center experience.
abstract: In patients with multiple myeloma the median overall survival is now approaching 5 years, following the introduction of autologous stem cell transplantation and targeted therapies. However, patients receiving conventional chemotherapy who have survived 10 years or longer have been repeatedly reported in the literature. From 723 patients with multiple myeloma seen in our department from January 1981 to June 2007, we selected 21 long-term (> or =10 years) survivors (2.9%) who had been treated with conventional chemotherapy. Potentially favourable prognostic factors, common to most patients, were: age < or =65 years; response to first-line chemotherapy; absence of Bence-Jones proteinuria; prolonged duration of response or stable disease irrespective of the primary regimen; maintenance therapy with interferon-alpha. The use of prognostic factors to identify a subset of low-risk patients could be of assistance in the selection of targeted treatments and the elucidation of poorly known features of myeloma biology.
authors.affiliation: Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Piazza Giulio Cesare 11, Bari, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Merchionne
authors.forename: Pasquale
authors.initials: P
authors.lastname: Procaccio
authors.forename: Franco
authors.initials: F
authors.lastname: Dammacco
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000503:physiopathology*; D011379:Prognosis; D013534:Survival
chemical_list: D000970:Antineoplastic Agents
references.citation: Blood. 1993 Mar 15;81(6):1428-34
references.pmid: 8453092
references.citation: J Clin Oncol. 2005 May 20;23(15):3412-20
references.pmid: 15809451
references.citation: J Clin Oncol. 2004 May 15;22(10):1857-63
references.pmid: 15111617
references.citation: Eur J Haematol. 1999 Feb;62(2):109-16
references.pmid: 10052714
references.citation: Br J Haematol. 2001 Jun;113(4):1020-34
references.pmid: 11442498
references.citation: Blood. 2003 Nov 1;102(9):3340-8
references.pmid: 12855563
references.citation: Br J Haematol. 1996 May;93(2):345-51
references.pmid: 8639427
references.citation: Cancer. 1972 Aug;30(2):382-9
references.pmid: 5051662
references.citation: N Engl J Med. 2003 Dec 25;349(26):2495-502
references.pmid: 14695409
references.citation: J Clin Invest. 1994 Dec;94(6):2317-25
references.pmid: 7989587
references.citation: Eur J Haematol. 2000 Sep;65(3):175-81
references.pmid: 11007053
references.citation: Blood. 1999 May 1;93(9):3064-73
references.pmid: 10216103
references.citation: J Clin Oncol. 2007 Jun 10;25(17):2434-41
references.pmid: 17485707
references.citation: Blood Rev. 1994 Mar;8(1):13-20
references.pmid: 8205006
references.citation: Br J Haematol. 1990 Nov;76(3):365-8
references.pmid: 2261347
references.citation: Br J Haematol. 1998 Sep;102(5):1115-23
references.pmid: 9753033
references.citation: Ann Hematol. 1998 Feb;76(2):67-72
references.pmid: 9540760
references.citation: N Engl J Med. 1996 Jul 11;335(2):91-7
references.pmid: 8649495
references.citation: Eur J Haematol. 2005 Nov;75(5):370-5
references.pmid: 16191085
references.citation: JAMA. 1969 Jun 2;208(9):1680-5
references.pmid: 5818682
references.citation: N Engl J Med. 2005 Jun 16;352(24):2487-98
references.pmid: 15958804
references.citation: J Immunol. 1991 Dec 15;147(12):4402-7
references.pmid: 1753108
references.citation: Eur J Cancer. 2006 Jul;42(11):1564-73
references.pmid: 16765041
references.citation: N Engl J Med. 1990 May 17;322(20):1430-4
references.pmid: 2184356
references.citation: N Engl J Med. 1983 Feb 10;308(6):314-6
references.pmid: 6823231
references.citation: Br J Haematol. 2003 Apr;121(2):251-8
references.pmid: 12694246
references.citation: Br J Haematol. 1994 Aug;87(4):832-4
references.pmid: 7986723
references.citation: Blood. 2005 Dec 15;106(13):4050-3
references.pmid: 16118317
references.citation: Acta Haematol. 2001;105(4):241-3
references.pmid: 11528099
references.citation: Eur J Cancer. 2003 Jan;39(1):31-7
references.pmid: 12504655
references.citation: J Clin Oncol. 2006 Jan 20;24(3):431-6
references.pmid: 16365178
references.citation: Haematologica. 2007 Oct;92(10):1399-406
references.pmid: 18024376
references.citation: J Intern Med. 1992 Feb;231(2):129-31
references.pmid: 1541934
references.citation: Cancer. 1984 May 15;53(10):2069-72
references.pmid: 6704893
references.citation: Arch Intern Med. 1985 Nov;145(11):2073-4
references.pmid: 4062460
references.citation: Ann Oncol. 2000 Nov;11(11):1427-36
references.pmid: 11142483
references.citation: Cancer. 1975 Sep;36(3):842-54
references.pmid: 1182674
references.citation: J Clin Oncol. 2007 May 20;25(15):1993-9
references.pmid: 17420512
references.citation: Cancer Treat Rep. 1984 Nov;68(11):1331-8
references.pmid: 6388832
references.citation: Br J Haematol. 2006 May;133(4):389-96
references.pmid: 16643445
references.citation: Haematologica. 1999 Apr;84(4):336-41
references.pmid: 10190948
references.citation: Br J Haematol. 1998 Jul;102(2):495-502
references.pmid: 9695964
references.citation: Eur Cytokine Netw. 1990 Oct-Nov;1(4):193-201
references.pmid: 2104241
references.citation: J Clin Oncol. 1998 Dec;16(12):3832-42
references.pmid: 9850028